Skip to main content

Table 2 Efficacy in patients treated to disease progression, adverse events in the absence of disease progression, and the intent-to-treat population

From: Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

Efficacy variable

Patients treated to PD

Patients treated to AEs

ITT population [18, 19]

nab-P + Gem

(n = 224)

Gem

(n = 233)

nab-P + Gem

(n = 98)

Gem

(n = 58)

nab-P + Gem

(n = 431)

Gem

(n = 430)

Overall survival, median, months

9.8

7.5

7.7

6.0

8.7

6.6

 Hazard ratio (95 % CI)

0.69 (0.56–0.84)

0.87 (0.60–1.27)

0.72 (0.62–0.83)

P value

<0.001

0.466

<0.001

Progression-free survival, median, months

6.0

3.8

5.5

5.0

5.5

3.7

 Hazard ratio (95 % CI)

0.62 (0.50–0.79)

0.63 (0.40–1.01)

0.69 (0.58–0.82)

P value

<0.001

0.053

<0.001

Overall response rate, %

27

9

19

10

23

7

 Complete response

<1

0

0

0

<1

0

 Partial response

26

9

19

10

23

7

 Stable disease

33

35

30

34

27

28

Response rate ratio (95 % CI)

3.12 (1.95–5.00)

1.87 (0.79–4.42)

3.19 (2.18–4.66)

P value

<0.001

0.137

<0.001

Disease control ratea

57

40

43b

42c

48

33

 Disease control rate ratio (95 % CI)

1.42 (1.17–1.72)

1.03 (0.71–1.49)

1.46 (1.23–1.72)

P value

<0.001

0.896

<0.001

  1. AE adverse event, Gem gemcitabine, ITT intent-to-treat, nab-P nab-paclitaxel, PD progressive disease
  2. aDisease control rate includes patients who achieved a complete or partial response or stable disease for ≥ 16 weeks
  3. bBased on 99 evaluable patients
  4. cBased on 59 evaluable patients